…
SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption. It also develops Evolve Mouse, a modified version of its bait technology containing the active ingredient cottonseed oil that limits reproduction of male and female mice. The company was incorporated in 2004 and is headquartered in Surprise, Arizona.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
SenesTech, Inc. develops and commercializes non-lethal fertility-control products for pest rodents, marketed to pest managers, municipalities and facility operators. Long-term growth may be driven by adoption of non-toxic control methods, regulatory approvals and geographic expansion, and recurring service revenue; investors may view this as exposure to an IP-backed alternative to conventional rodenticides.
Primary risk is limited commercial scale and dependence on a single product, which creates adoption, regulatory and financing vulnerability.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -6.38M | -6.18M | -7.71M | -9.70M | -8.27M |
| Net income | -6.38M | -6.18M | -7.71M | -9.71M | -7.98M |
| Selling general administrative | 5.93M | 5.25M | 6.70M | 7.59M | 7.22M |
| Selling and marketing expenses | 0.26M | 0.29M | 0.32M | 0.63M | - |
| Gross profit | 1.39M | 1.00M | 0.54M | 0.46M | 0.22M |
| Reconciled depreciation | 0.14M | 0.16M | 0.14M | 0.18M | 0.30M |
| Ebit | -6.36M | -6.16M | -7.71M | -9.67M | -8.93M |
| Ebitda | -6.23M | -6.01M | -7.57M | -9.69M | -8.93M |
| Depreciation and amortization | 0.14M | 0.16M | 0.14M | -0.02M | 0.00M |
| Operating income | -6.50M | -6.25M | -7.73M | -9.67M | -8.93M |
| Other operating expenses | 8.73M | 8.11M | 8.93M | 10.69M | 9.51M |
| Interest expense | 0.02M | 0.02M | 0.00M | 0.00M | 0.01M |
| Interest income | 0.14M | 0.06M | 0.02M | 0.01M | 0.00M |
| Net interest income | 0.12M | 0.03M | 0.02M | 0.01M | -0.01M |
| Income tax expense | - | - | 0.03M | 0.02M | -0.29M |
| Total revenue | 2.22M | 1.86M | 1.19M | 1.02M | 0.58M |
| Total operating expenses | 7.89M | 7.25M | 8.27M | 10.14M | 9.15M |
| Cost of revenue | 0.83M | 0.85M | 0.65M | 0.56M | 0.36M |
| Total other income expense net | 0.12M | 0.07M | 0.02M | -0.02M | 0.67M |
| Net income from continuing ops | -6.38M | -6.18M | -8.12M | -9.70M | -8.27M |
| Net income applicable to common shares | - | - | - | -9.70M | -8.27M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 12.84M | 3.28M | 7.29M | 6.78M | 11.50M |
| Other current assets | 0.30M | 0.38M | 0.39M | 0.38M | 0.25M |
| Total liab | 3.27M | 0.77M | 0.94M | 1.50M | 1.47M |
| Total stockholder equity | 9.57M | 2.51M | 6.35M | 5.28M | 10.04M |
| Other current liab | 0.38M | 0.28M | 0.37M | 0.56M | 0.58M |
| Common stock | 0.01M | 0.00M | 0.01M | 0.00M | 0.01M |
| Capital stock | 0.01M | 0.00M | 0.01M | 0.00M | 0.01M |
| Retained earnings | -142.48M | -136.10M | -129.91M | -122.20M | -112.51M |
| Other assets | - | - | - | 0.02M | 0.02M |
| Cash | 7.58M | 1.31M | 5.39M | 4.78M | 9.33M |
| Total current liabilities | 0.80M | 0.56M | 0.79M | 1.32M | 0.94M |
| Current deferred revenue | 0.03M | 0.01M | 0.02M | 0.04M | - |
| Net debt | -4.90M | -1.04M | -4.99M | -4.42M | -8.77M |
| Short term debt | 0.20M | 0.06M | 0.25M | 0.18M | 0.03M |
| Short long term debt | 0.06M | 0.06M | 0.03M | - | 0.03M |
| Short long term debt total | 2.68M | 0.26M | 0.41M | 0.36M | 0.56M |
| Other stockholder equity | 152.04M | 138.61M | 136.26M | 127.48M | 122.53M |
| Property plant equipment | - | - | - | 0.64M | 0.84M |
| Total current assets | 10.06M | 2.81M | 6.67M | 6.12M | 10.66M |
| Net tangible assets | - | - | - | 5.28M | 10.04M |
| Short term investments | 0.99M | 0.00M | - | - | - |
| Net receivables | 0.20M | 0.34M | 0.10M | 0.11M | 0.08M |
| Long term debt | 0.14M | 0.21M | 0.16M | - | - |
| Inventory | 0.99M | 0.79M | 0.80M | 0.85M | 1.00M |
| Accounts payable | 0.18M | 0.21M | 0.15M | 0.54M | 0.33M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | 0.04M | 0.06M | 0.02M | 0.02M | - |
| Non current assets total | 2.78M | 0.47M | 0.62M | 0.66M | 0.84M |
| Capital lease obligations | 2.47M | 0.00M | 0.22M | 0.36M | 0.52M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.96M | -0.06M | -0.12M | -0.17M | -0.10M |
| Change to liabilities | - | - | - | 0.25M | -0.07M |
| Total cashflows from investing activities | -1.10M | -0.06M | -0.15M | -0.17M | -0.10M |
| Net borrowings | -0.06M | -0.02M | 0.11M | -0.03M | -0.09M |
| Total cash from financing activities | 13.12M | 2.00M | 8.34M | 4.20M | 13.56M |
| Change to operating activities | - | - | - | -0.17M | 0.25M |
| Net income | -6.38M | -6.18M | -7.71M | -9.70M | -8.27M |
| Change in cash | 6.27M | -4.09M | 0.62M | -4.55M | 5.68M |
| Begin period cash flow | 1.31M | 5.39M | 4.78M | 9.33M | 3.64M |
| End period cash flow | 7.58M | 1.31M | 5.39M | 4.78M | 9.33M |
| Total cash from operating activities | -5.75M | -6.03M | -7.57M | -8.58M | -7.78M |
| Issuance of capital stock | 2.71M | 0.04M | 7.23M | 4.23M | 12.42M |
| Depreciation | 0.14M | 0.16M | 0.14M | 0.18M | 0.30M |
| Other cashflows from investing activities | 2.00M | 0.03M | - | - | - |
| Change to inventory | -0.20M | 0.00M | 0.06M | 0.15M | -0.06M |
| Change to account receivables | 0.12M | -0.24M | 0.02M | -0.04M | -0.05M |
| Sale purchase of stock | - | - | -0.01M | - | - |
| Other cashflows from financing activities | 13.12M | 1.98M | 2.82M | -0.17M | 1.23M |
| Change to netincome | - | - | - | 0.74M | 0.12M |
| Capital expenditures | 0.14M | 0.08M | 0.15M | 0.17M | 0.10M |
| Change in working capital | 0.12M | -0.30M | -0.54M | 0.19M | 0.07M |
| Stock based compensation | 0.26M | 0.33M | 0.56M | 0.71M | 0.77M |
| Other non cash items | 0.12M | -0.03M | -0.00M | 0.03M | -0.65M |
| Free cash flow | -5.89M | -6.12M | -7.71M | -8.75M | -7.88M |
Sector: Basic Materials Industry: Specialty Chemicals
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SNES SenesTech Inc |
0.03 2.85% |
0.92 | - | 3.40 | 1.92 | 0.77 | 0.91 | 0.11 |
| LIN Linde plc Ordinary Shares |
-0.71 0.13% |
525.84 | 33.77 | 28.90 | 6.56 | 5.42 | 7.03 | 18.92 |
| AIQUY Air Liquide SA ADR |
-0.01 0.02% |
42.70 | 30.69 | 24.81 | 4.70 | 4.10 | 4.36 | 15.61 |
| AIQUF L'Air Liquide S.A |
0.01 0.00% |
213.36 | 29.78 | 22.68 | 4.54 | 3.98 | 4.50 | 15.90 |
| SHW Sherwin-Williams Co |
0.06 0.02% |
355.82 | 33.33 | 27.40 | 3.38 | 20.60 | 3.88 | 21.36 |
SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption. It also develops Evolve Mouse, a modified version of its bait technology containing the active ingredient cottonseed oil that limits reproduction of male and female mice. The company was incorporated in 2004 and is headquartered in Surprise, Arizona.
13430 North Dysart Road, Surprise, AZ, United States, 85379
928 779 4143
23
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas C. Chesterman M.B.A. | Exec. VP, CFO, Treasurer & Assistant Sec. | 1959 |
| Dr. Steven C. Krause Ph.D. | Exec. VP of Sales & Marketing | 1960 |
| Mr. Kenneth S. Siegel | Exec. Director | 1956 |
| Mr. Joel Fruendt | CEO & Director | 1961 |
| Ms. Kim Patrice Wolin | Exec. VP of Operations & Sec. | 1955 |
| Ms. Nicole Williams | Chief Strategy Officer | 1980 |
| Mr. Paul M. Palz | VP & Corp. Controller | NA |
| Robert Blum | Investor Relations | NA |
| Mr. Joel L. Fruendt | CEO, President & Director | 1961 |
| Mr. Thomas C. Chesterman M.B.A. | Executive VP, CFO, Treasurer & Secretary | 1959 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.